Singapore markets closed
Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,691.66 +437.30 (+0.66%) CMC Crypto 200
1,381.61 -36.26 (-2.56%)
OCGN Jun 2024 2.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:37AM EDT. Market open.
| Previous close | 0.4700 |
| Open | 0.5300 |
| Bid | 0.4000 |
| Ask | 1.4000 |
| Strike | 2.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.5300 - 0.5400 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.07k |
ZacksIs Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
ZacksOcugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.
GlobeNewswireData and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and Safety Monitoring Board (DSMB) Review for its Phase 1/2
© 2024 Yahoo. All rights reserved.